VOLITIONRX LTD — Director's Dealing 2013

Aug 27, 2013

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2012-12-31

Reporting Person: Reynolds Cameron John (Director, PRESIDENT AND CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON STOCK	202344	Direct
COMMON STOCK	2042088	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
OPTION	$3	2015-05-25	COMMON STOCK (20000)	20000	Direct
OPTION	$3	2015-11-25	COMMON STOCK (20000)	20000	Direct
OPTION	$4	2016-05-25	COMMON STOCK (20000)	20000	Direct
OPTION	$4	2016-11-25	COMMON STOCK (20000)	20000	Direct
OPTION	$5	2017-05-25	COMMON STOCK (20000)	20000	Direct
OPTION	$5	2017-11-25	COMMON STOCK (20000)	20000	Direct
WARRANT	$2.6	2016-05-10	COMMON STOCK (1172)	1172	Direct

Footnotes

F1: On October 6, 2011, Cameron Reynolds was appointed as President, Chief Executive Officer, and Director of the Company.

F2: The shares are held by Concord International, Inc. in trust. Mr. Reynolds is a potential beneficiary of the trust, however, any distribution will be determined by the trustee and there is no actual entitlement to a distribution of the shares.

F3: Unit Price of $1.75 for 2,343 shares of common stock reported in Table 1, which included a warrant to purchase 1,172 Shares at $2.60 for four years.